Evoke receives notice of allowance for two additional patent applications

Evoke Pharma (EVOK) announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company’s robust intellectual property estate for its innovative GIMOTI nasal spray. The two patent applications, U.S. 17/366,839 and U.S. 17/366,818, entitled “Nasal Formulations of Metoclopramide,” provide Evoke with additional claims protecting the intranasal administration of metoclopramide for the treatment of gastroparesis. When issued, these patents will bolster the Company’s position as the provider of the only FDA-approved, non-oral, patient administered therapy for acute and recurrent diabetic gastroparesis in the US. The two patents are expected to be Orange Book listable and expire at the end of 2029.